somatostatin analogue
Lanreotide
Answer
Lanreotide is authorised or registered in the US, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 9 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 125 registered trials, 10 of them running. Brand names on the FDA label register: Lanreotide Acetate and Somatuline Depot.
RegulatorTrial register10 regulators' registers, read 2026-08-31 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
125 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 30 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 89 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Not on the register | EMA, ema | 2026-08-31 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Lanreotide changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 125 trials
| 2024-516616-24-00 | A Phase 3 randomized 3-arm trial (double-blind Debio 4126, placebo control, and open-label Debio 4126), to assess the efficacy and no status recorded · register updated 2026-09-23 |
|---|---|
| NCT06878664 | Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors currently recruiting participants · register updated 2026-09-16 |
| 2023-509334-19-00 | Trial title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) no status recorded · register updated 2026-08-31 |
| 2023-508723-12-00 | A randomized, multi-center, open-label, active-controlled Phase 3 trial to assess the efficacy and safety of octreotide subcutaneo no status recorded · register updated 2026-08-10 |
| NCT07087054 | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen currently recruiting participants · register updated 2026-08-04 |
| NCT05050942 | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET running, but no longer enrolling · register updated 2026-07-28 |
| 2023-505884-35-00 | Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial no status recorded · register updated 2026-06-17 |
| NCT07534371 | Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort running, but no longer enrolling · register updated 2026-04-16 |
| NCT05048901 | Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors currently recruiting participants · register updated 2026-04-09 |
| NCT02127437 | Lanreotide In Polycystic Kidney Disease Study completed · register updated 2026-04-08 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.